(Total Views: 330)
Posted On: 10/15/2025 5:26:08 PM
Post# of 158065
Quote:
In mTNBC about 76% of patients died during the first year,
Here should be more ,
So after the trial we may read that when LL is added to the treatment in mCRC , mortality is higher then only with SOC.
What hampered survival results from the combined trials and the study was the number of patients who were in dire straits. 32% of patients had 2 prior treatments and 25% had 3 to 5 prior treatment regimens and this was after metastasis had occurred. It's unknown how many treatments were done prior to metastasis. 29% had brain metastasis which is so bad that it was excluded in the trials for Trodelvy. Add to that, that 36% of patients had only the 350mg dose and only 11% of patients received a 700mg dose.
(10)
(0)
